Medical Devices China

China Insulin Pens Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

China Insulin Pens Market Industry Trends and Forecast to 2034: Segmented by (Type, Needle, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

China · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $242.2 Mn Placeholder estimate
Estimate 2025 $264.7 Mn 7.8% of the global market
Projected 2034 $589.4 Mn 122.6% Adds $324.6 Mn over 9 forecast years
CAGR 2025–2034 9.3% Faster than 42% of 193 Medical Devices markets here
Key players 6 +1
  • China is 7.83% of the global market.
  • In APAC, the largest is China (this report) at $264.7 Mn.
  • Fastest growing: India at 11.3% a year.
  • China ranks 1st of 14 by size in APAC.

Market size projection

China

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$324.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Insulin Pens Market market size by year, China
YearMarket sizeChange that yearSince 2025
2024 (estimate) $242.2 Mn — —
2025 (base) $264.7 Mn +$22.5 Mn —
2026 (forecast) $289.4 Mn +$24.6 Mn +9.3%
2027 (forecast) $316.3 Mn +$26.9 Mn +19.5%
2028 (forecast) $345.7 Mn +$29.4 Mn +30.6%
2029 (forecast) $377.8 Mn +$32.1 Mn +42.7%
2030 (forecast) $413.0 Mn +$35.1 Mn +56%
2031 (forecast) $451.4 Mn +$38.4 Mn +70.5%
2032 (forecast) $493.3 Mn +$42.0 Mn +86.4%
2033 (forecast) $539.2 Mn +$45.9 Mn +103.7%
2034 (forecast) $589.4 Mn +$50.1 Mn +122.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

China Insulin Pens Market Analysis at a glance
Market size, 2025$264.7 Mn placeholder estimate
Forecast, 2034$589.4 Mn placeholder estimate
Growth (CAGR), 2025–20349.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType and needle (see all)
Key playersNovo Nordisk A/S, Eli Lilly and Company, Sanofi, Ypsomed, Owen Mumford and 1 more (see all)
Regulator in ChinaNMPASource: National Medical Products Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The China Insulin Pens Market Analysis Executive Summary

Insulin pens are handheld injectors that give set doses of insulin, as a simpler option than vials and syringes.

Key segments of the insulin pens market include type (Prefilled Pens, Reusable Pens and Connected Pens) and needle (Standard Needles and Safety Needles).

Bar chart: China Insulin Pens market size, 2024–2034, placeholder estimates. $242.2 Mn in 2024, $264.7 Mn in 2025 and $589.4 Mn in 2034, 9.3% CAGR.
China Insulin Pens market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

China Insulin Pens Market Dynamics

Market Growth Drivers

Rising numbers of people with diabetes, a shift to tools that track and deliver treatment automatically, and more insurance cover are driving the insulin pens market.

Opportunity

Connected devices, lower-priced sensors and new insulins and pills give the insulin pens market room to grow.

Market Restraints

High costs for people without cover, price competition and uneven access to care in low-income countries hold back the insulin pens market.

Competitive Landscape for Insulin Pens Market in China

The insulin pens market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Insulin Pens Market in China

Insulin Pens in China: rules, payment and health figures

Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered.⁠[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.⁠[2] Diabetes (ages 20–79): 11.9% of people 20–79 in 2024, the latest World Bank figure for China.⁠[3]

[1] National Medical Products Administration. Checked 14 Nov 2026.

[2] National Healthcare Security Administration. Checked 14 Nov 2026.

[3] World Bank Open Data, Diabetes (ages 20–79) (% of people 20–79). Retrieved 21 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how insulin pens products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in China.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Insulin Pens right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Insulin Pens in context

China compared

  • Diabetes (ages 20–79): 11.9% of people 20–79 (2024). World: 10.8% of people 20–79 (2024). 4th highest of the 18 countries we cover in APAC.[1]
  • Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 6th highest of the 17 countries we cover in APAC.[2]
  • Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 17 countries we cover in APAC.[3]

[1] World Bank Open Data, Diabetes (ages 20–79) (% of people 20–79). Retrieved 21 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Insulin Pens market in China?
Placeholder estimate: about $264.7 Mn in 2025, rising to about $589.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Insulin Pens market in China growing?
Placeholder estimate: about 9.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Insulin Pens market report cover?
The report splits the market by type (Prefilled Pens, Reusable Pens, Connected Pens) and needle (Standard Needles, Safety Needles).
Who are the key players in the Insulin Pens market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Ypsomed, Owen Mumford and BD (Becton, Dickinson).
What is driving the Insulin Pens market?
Rising numbers of people with diabetes, a shift to tools that track and deliver treatment automatically, and more insurance cover are driving the insulin pens market.
Who regulates Insulin Pens in China?
Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered. Source: National Medical Products Administration. Checked 14 Nov 2026.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
What does World Bank report for China?
Diabetes (ages 20–79): 11.9% of people 20–79 in 2024, the latest World Bank figure. Source: World Bank Open Data, Diabetes (ages 20–79) (% of people 20–79). Retrieved 21 Nov 2026.
How many people in China are 65 or older?
14.9% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 21 Nov 2026.
Back to Catalogue

Related Medical Devices reports in China

See all

Related on diabetes

See the topic